Sirnaomics

Oct 04, 2024

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

Sep 19, 2024

Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology

Jul 08, 2024

Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics

Jun 28, 2024

Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

Jun 13, 2024

Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy

Mar 28, 2024

Sirnaomics Announces 2023 Annual Results

Mar 12, 2024

Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference

Feb 05, 2024

Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024

Jan 24, 2024

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors